I-Mab Biopharma Overview
- Founded
- 2016
- Status
- Public
- Employees
- 228
- Stock Symbol
- IMAB
- Investments
- 1
- Share Price
- $20.91
- (As of Monday Closing)
I-Mab Biopharma General Information
Description
I-MAB Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in 2022. Core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor; uliledlimab, a potential best-in-class CD73 inhibitor; and efineptakin alfa, a potential first-in-class long-acting IL-7 drug for tumors and treatment-associated lymphopenia.
Contact Information
Website
www.i-mabbiopharma.com
Formerly Known As
Third Venture Biopharma
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Primary Office
- West Tower, 88 Shangke Road, Pudong New District
- Suites 802, 505, 702
- Shanghai, 201210
- China
+86 021 0000 0000
I-Mab Biopharma Timeline
I-Mab Biopharma Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $20.91 | $21.15 | $20.20 - $85.40 | $1.69B | 79.9M | 731K | $0.66 |
I-Mab Biopharma Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 | FY 2018 31-Dec-2018 |
|---|---|---|---|---|
| EV | 5,725,999 | 3,115,533 | ||
| Revenue | 235,357 | 223,296 | 4,342 | 8,130 |
| EBITDA | (56) | 69,914 | (211,863) | (58,542) |
| Net Income | (3,426) | 68,163 | (210,134) | (60,894) |
| Total Assets | 950,954 | 969,463 | 248,338 | 345,390 |
| Total Debt | 6,364 | 2,082 | 18,937 | 21,373 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
I-Mab Biopharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore I-Mab Biopharma‘s full profile, request access.
Request a free trialI-Mab Biopharma Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
I-MAB Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial
Drug Discovery
Shanghai, China
228
As of 2020
00000
000000000
00000
0000000
esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt i
0000 000000000
San Diego, CA
00.000
000000000
00.000
000-000
re dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur
0000 000000000
Vienna, VA
00
As of 0000
000.00
000000000
000.00
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialI-Mab Biopharma Competitors (45)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Nascent Biotech | Corporation | San Diego, CA | 00.000 | 000000000 | 00.000 | |
| 000-000 | Corporate Backed or Acquired | Vienna, VA | 00 | 000.00 | 000000000 | 000.00 |
| 0000000 0000000000 | Formerly VC-backed | Dallas, TX | 00 | 00000 | 000000&0 | 00000 |
| 00000000 000000000 | Formerly VC-backed | Newtown, PA | 00 | 00000 | 00000000 | 00000 |
| 00000000 000000000 | Formerly PE-Backed | Suzhou, China | 0000 | 00.000 | 000000000 | 00.000 |
I-Mab Biopharma Patents
I-Mab Biopharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210317224-A1 | Anti-claudin 18.2 and anti-4-ibb bispecific antibodies and uses thereof | Pending | 12-Aug-2019 | 00000000000 | |
| CA-3117740-A1 | Anti-claudin 18.2 and anti-4-1bb bispecific antibodies and uses thereof | Pending | 12-Aug-2019 | 00000000000 | |
| AU-2020329466-A1 | Anti-claudin 18.2 and anti-4-1bb bispecific antibodies and uses thereof | Pending | 12-Aug-2019 | 00000000000 | |
| EP-3853257-A1 | Anti-claudin 18.2 and anti-4-1bb bispecific antibodies and uses thereof | Pending | 12-Aug-2019 | 00000000000 | |
| AU-2020261961-A1 | Human pd-l1 antibodies | Pending | 26-Apr-2019 | C07K16/2827 |
I-Mab Biopharma Executive Team (12)
I-Mab Biopharma Board Members (8)
| Name | Representing | Role | Since |
|---|---|---|---|
| Chun Kwok Au | Self | Board Member | 000 0000 |
| Conor Yang | Self | Board Member | 000 0000 |
| Jielun Zhu | I-Mab Biopharma | Director & Chief Strategy Officer | 000 0000 |
| Jingwu Zang Ph.D | I-Mab Biopharma | Chairman & Board Member | 000 0000 |
| Joan Shen | I-Mab Biopharma | Chief Executive Officer & Board Member | 000 0000 |
I-Mab Biopharma Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialI-Mab Biopharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
This information is available in the PitchBook Platform. To explore I-Mab Biopharma‘s full profile, request access.
Request a free trialI-Mab Biopharma Investments (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000000000 0 | 23-Mar-2017 | 0000000000 | 00000 | Biotechnology |